Immunine (Human Coagulation Factor Ix)

• Immunine is a recombinant factor IX product used in the intrinsic coagulation pathway for hemophilia B management.
• Hemophilia B (Factor IX deficiency): replaces missing factor IX to correct the clotting defect.
• Bleeding episodes in hemophilia B: used to stop or prevent spontaneous or traumatic bleeding.
• Peri‑operative management in hemophilia B: provides hemostasis during surgical procedures.

• Human Coagulation Factor IX supplied by Immunine restores the deficient clotting factor in the intrinsic pathway of the coagulation cascade. The infused factor IX binds to activated factor VIII on phospholipid surfaces, enabling conversion of factor X to Xa, which ultimately leads to thrombin generation and fibrin clot formation, correcting the bleeding tendency in hemophilia B patients.

Common Side Effects

• Infusion‑related reactions such as mild fever, chills, or headache.
• Nausea or mild gastrointestinal discomfort.
• Transient hypertension or mild blood pressure fluctuations.
• Local site irritation at the infusion site.
• Fatigue or mild malaise.

Serious or Rare Side Effects

• Anaphylactic or severe allergic reactions.
• Development of neutralizing inhibitors (antibodies) against factor IX.
• Thrombotic events including deep vein thrombosis.
• Severe hemolysis or renal impairment.
• Life‑threatening bleeding due to inhibitor formation.
• Disseminated intravascular coagulation (rare).

• Immunine requires careful clinical monitoring and individualized dosing.
• Dose individualization: dosing is based on patient’s factor IX activity levels and clinical need.
• Monitoring: regular assessment of factor IX plasma levels and bleeding signs is essential.
• Allergy history: evaluate for prior hypersensitivity to plasma‑derived or recombinant clotting products.
• Pregnancy and lactation: use only if benefits outweigh potential risks; data are limited.
• Inhibitor development: monitor for antibodies that may reduce efficacy.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Immunine may interact with other agents affecting coagulation.

Major Interactions (Avoid)

• Concomitant use of pro‑coagulant agents (e.g., activated prothrombin complex concentrates) may increase thrombosis risk.
• Concurrent anticoagulants (e.g., warfarin, direct oral anticoagulants) may counteract the therapeutic effect.
• Use with other factor IX products may lead to additive clotting activity.

Moderate Interactions (Monitor Closely)

• Live attenuated vaccines may have altered efficacy when administered concurrently.
• Certain antibiotics that affect protein synthesis could impact product stability.
• Immunosuppressive therapies may influence inhibitor development risk.